Visual Outcomes in Patients Contralaterally Implanted With PanOptix Pro and Clareon Vivity Compared to Bilateral Implantation of PanOptix Pro
A legfontosabb adatok
- Ki végzi
- Brian Shafer
- Hol
- Alexandria, Bala-Cynwyd, Baltimore, Bozeman és Plymouth Meeting (Egyesült Államok)Mind a 5 helyszín megnézése
- Azonosító
- Állapot
- Csak meghívásos
- Résztvevők
- 346 fő, tervezett
- Kezdés
- 2025. aug. 5.
- Várható befejezés
- 2026. dec. 1.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Clareon PanOptix Pro and Clareon Vivity Intraocular Lens
- Clareon PanOptix Pro Intraocular Lenses
- A regiszteradat frissítve
- 2025. szeptember 22.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 21 feltétel megnézéseKevesebb
Ki vehet részt
- Bilateral diagnosis of age-related cataracts
- Planned bilateral cataract removal by phacoemulsification with either:
- Contralateral implantation of Clareon PanOptix Pro/PanOptix Pro Toric in one eye and Clareon Vivity/Vivity Toric in the fellow eye, or
- Bilateral implantation of Clareon PanOptix Pro/PanOptix Pro Toric
- Expected best monocular corrected distance visual acuity (BCDVA) of 0.1 logMAR (Snellen 20/25) or better in both eyes postoperatively, as determined by the surgeon
- Residual astigmatism expected to be ≤0.50 diopters in both eyes postoperatively (using toric IOLs or arcuate incisions as needed)
- Normal ocular findings aside from cataracts
Ki nem vehet részt
- Previous history of any ocular surgery, including corneal refractive surgery
- Any planned simultaneous or combined procedures at the time of cataract surgery (e.g., MIGS)
- Preexisting macular disease or other retinal degenerative disease expected to cause vision loss
- Severe dry eye disease
- Any condition (in the investigator's opinion) that may affect study endpoints
- History of amblyopia or monofixation syndrome with poor stereoscopic vision
- Any active ocular infection or inflammation
- Glaucoma
- Nystagmus or strabismus
- Zonular laxity or dehiscence, pseudoexfoliation
- Subjects desiring monovision
- Total corneal higher-order aberrations (HOA) greater than 0.6 microns
- Participation in another clinical study that could interfere with study results
- Pregnant, breastfeeding, or planning to become pregnant during the study (as determined by verbal inquiry)
Helyszínek itt: Egyesült Államok
- Vance Thompson VisionAlexandria, Egyesült ÁllamokCsak meghívásos
- Main Line Surgery CenterBala-Cynwyd, Egyesült ÁllamokCsak meghívásos
- VIP Eye CareBaltimore, Egyesült ÁllamokCsak meghívásos
- Vance Thompson VisionBozeman, Egyesült ÁllamokCsak meghívásos
- Shafer Vision InstitutePlymouth Meeting, Egyesült ÁllamokCsak meghívásos
A vizsgálatról
Mit akar kideríteni a vizsgálat
Title:
A teljes eredeti leírásKevesebb
Visual Outcomes in Patients Contralaterally Implanted with PanOptix Pro and Clareon Vivity Compared to Bilateral Implantation of PanOptix Pro
Sponsor:
Brian Shafer, MD, Shafer Vision Institute
Objective:
To compare visual outcomes and patient-reported satisfaction in cataract patients receiving either:
Contralateral implantation (PanOptix Pro in one eye, Clareon Vivity in the other)
Bilateral PanOptix Pro implants
Key hypotheses:
Contralateral implantation is non-inferior for binocular best-corrected distance visual acuity (BCDVA) at 4 m.
Contralateral implantation yields superior visual disturbance outcomes (less halo, glare, starburst).
Design:
Prospective, randomized, double-masked, two-arm, multicenter study
N = 346 subjects (173 per arm)
5 surgeons across 4 sites
All patients undergo bilateral phacoemulsification aiming for emmetropia
Randomized 1:1 to:
Arm 1: PanOptix Pro (dominant eye) + Clareon Vivity (non-dominant eye)
Arm 2: Bilateral PanOptix Pro
Surgical Details:
Femtosecond laser optional
Second eye surgery ≤4 weeks after first
Toric IOLs or arcuate incisions for residual astigmatism ≤0.50 D
Biometry with ARGOS, IOLMaster 700, or Lenstar
Toric alignment with ORA, Callisto, etc.
Assessments:
Visual acuity at 4 m, 66 cm, 40 cm, 33 cm in photopic and mesopic conditions
Defocus curves, contrast sensitivity (with/without glare)
Manifest refraction
Patient-reported outcomes via IOLSAT and QUVID questionnaires
Masking: subjects and assessors unaware of IOL assignments
Endpoints (at 3 months):
Primary: Binocular BCDVA (4 m)
Secondary: DCIVA, DCNVA, UDVA, UIVA, UNVA, defocus curves, refractive outcomes, visual disturbance scores
Exploratory: Mesopic VA, low contrast VA, contrast sensitivity, satisfaction scores
Eligibility Criteria:
Adults with bilateral age-related cataracts
Plan for bilateral phacoemulsification
Expected postop monocular BCDVA ≤0.1 logMAR (20/25)
Residual astigmatism ≤0.50 D
Exclusions include corneal pathology, macular disease, glaucoma, prior ocular surgery, amblyopia, severe dry eye, high HOA (>0.6 um), monovision preference, active infection/inflammation, pregnancy
Statistics:
Non-inferiority margin: 0.1 logMAR
Superiority testing for visual disturbances
Step-down testing hierarchy for primary and secondary outcomes
Sample size powered for 80% at α=0.05, accounting for 10% dropout
Two-proportion Z-tests for dysphotopsia rates
Safety Monitoring:
Adverse Events (AEs) and Serious Adverse Events (SAEs) captured
Definitions, severity grading, and reporting procedures specified
Protocol deviations documented and reported per IRB requirements
Data Handling:
Data anonymized via subject numbers
Stored securely (locked cabinets, password-protected systems)
Study registered at ClinicalTrials.gov
Visit Schedule:
Screening: Consent, eligibility, history
1st \& 2nd Eye Surgery Visits
3-Month Post-Op Visit: Comprehensive visual assessments, questionnaires, AE review
A vizsgálat 2 csoportja
- Contralateral PanOptix Pro and Clareon VivityA vizsgált kezelés
Subjects randomized to this arm will receive bilateral cataract surgery with contralateral implantation: Alcon Clareon PanOptix Pro or PanOptix Pro Toric IOL in one eye and Alcon Clareon Vivity or Vivity Toric IOL in the fellow eye. The Vivity IOL will be implanted in the dominant eye, with all surgeries targeting emmetropia. Residual astigmatism will be managed to ≤0.50 diopters using toric IOLs or arcuate incisions as needed.
Kezelés: Clareon PanOptix Pro and Clareon Vivity Intraocular Lens
- Bilateral PanOptix ProMár használt kezelés, összehasonlításként
Subjects randomized to this arm will receive bilateral cataract surgery with implantation of Alcon Clareon PanOptix Pro or PanOptix Pro Toric IOLs in both eyes. All eyes will be targeted for emmetropia, and residual astigmatism will be controlled to ≤0.50 diopters using toric IOLs or arcuate incisions as appropriate.
Kezelés: Clareon PanOptix Pro Intraocular Lenses
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- A regiszteradat frissítve
- 2025. szeptember 22.